Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06643390 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-2225 in Healthy Participants (MK-2225-003)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06643390 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 32 participants.
The verdict
NCT06643390, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.
Interventions
- OTHER Placebo
- DRUG MK-2225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2025-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06643390
The ClinicalTrials.gov registry entry for NCT06643390 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06643390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06643390 about?
NCT06643390 is a clinical study titled "A Study of MK-2225 in Healthy Participants (MK-2225-003)". The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.
What is the current status of trial NCT06643390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2023-11-21. Estimated completion is 2025-07-14.
What interventions are being tested in trial NCT06643390?
The interventions under investigation include: Placebo (OTHER), MK-2225 (DRUG).
Who is sponsoring clinical trial NCT06643390?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.